News
-
-
-
PRESS RELEASE
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen expands pipeline with Simcere Zaiming's novel antibody drug conjugate SIM0613 targeting LRRC15 protein for enhanced tumor penetration and anti-tumor activity. Phase I expected in H2 2026 -
-
-
-
-
-
-
PRESS RELEASE
Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Alphinat Inc. announces audited profit of $120,155 for the fiscal year ended August 31, 2025. The company focuses on SmartGuide solutions for government clients offering productivity and low Total Cost of Ownership (TCO)